Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma

• Published in: International journal of radiation oncology, biology, physics Vol. 16; no. 6; p. 1389
• Main Authors: Deutsch, M, Green, S B, Strike, T A, Burger, P C, Robertson, J T, Selker, R G, Shapiro, W R, Mealey, Jr, J, Ransohoff, 2nd, J, Paoletti, P
• Format: Journal Article
• Language: English
• Published: United States 01-06-1989
• Subjects: Adolescent; Adult; Aged; Astrocytoma - drug therapy; Astrocytoma - radiotherapy; Astrocytoma - surgery; Carmustine - therapeutic use; Combined Modality Therapy; Glioblastoma - drug therapy; Glioblastoma - radiotherapy; Glioblastoma - surgery; Glioma - drug therapy; Glioma - radiotherapy; Glioma - surgery; Glioma - therapy; Humans; Middle Aged; Misonidazole - therapeutic use; Multicenter Studies as Topic; Prognosis; Radiotherapy Dosage; Random Allocation; Streptozocin - therapeutic use; Supratentorial Neoplasms - drug therapy; Supratentorial Neoplasms - radiotherapy; Supratentorial Neoplasms - surgery; Supratentorial Neoplasms - therapy
• ISSN: 0360-3016
• DOI: 10.1016/0360-3016(89)90939-5

In Brain Tumor Cooperative Group Study 77-02, eleven institutions randomized 603 adult patients with supratentorial malignant glioma to one of four treatment groups following surgery: conventional radiotherapy (6000 cGy in 30-35 fractions) + BCNU, conventional radiotherapy + streptozotocin, hyperfractionated (twice daily) radiotherapy (6600 cGy in 60 fractions) + BCNU, and conventional radiotherapy with misonidazole followed by BCNU. Data were analyzed for the total randomized population and for the 557 patients (86% with glioblastoma multiforme) who met protocol eligibility specifications (including confirmed histopathology on central review). Median survival was approximately 10 months following randomization. Overall there was no statistically significant difference in survival among the four groups. Among non-glioblastoma patients, the misonidazole group appeared to have poor survival. Peripheral neuropathy was a dose-limiting toxicity with misonidazole. It is concluded that neither the addition of misonidazole nor hyperfractionated radiotherapy as given in this protocol offered any advantage over conventional radiotherapy plus either BCNU or streptozotocin for treatment of malignant glioma.